Clearance of hepatitis C virus after newly acquired infection in injection drug users

被引：59

作者：

Jauncey, M

Micallef, JM

Gilmour, S

Amin, J

White, PA

Rawlinson, W

Kaldor, JM

van Beek, I

Dore, GJ

机构：

[1] Univ New S Wales, Kirketon Rd Ctr, SE Sydney Area Hlth Serv, Sydney, NSW, Australia

[2] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia

[3] Univ New S Wales, Fac Sci, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia

[4] Prince Wales Hosp, Dept Microbiol, Div Virol, Sydney, NSW, Australia

[5] New S Wales Dept Hlth, New S Wales Publ Hlth Officer Training Program, Sydney, NSW, Australia

来源：

JOURNAL OF INFECTIOUS DISEASES | 2004年 / 190卷 / 07期

关键词：

D O I：

10.1086/423943

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A retrospective cohort of injection drug users with newly acquired hepatitis C virus (HCV) infection was established to examine viral clearance. Newly acquired HCV infection was defined by anti-HCV antibody seroconversion within a 2-year interval. Stored serum samples were tested for HCV RNA, with viral clearance defined as greater than or equal to2 consecutive negative HCV RNA test results after infection. Ninety-nine cases of HCV infection were identified; 57 had greater than or equal to2 HCV RNA test results after infection. Viral clearance occurred in 24 (42%) cases, with Kaplan-Meier estimated probabilities of 23%, 38%, and 40% at 6, 12, and 24 months, respectively.

引用

页码：1270 / 1274

页数：5

共 15 条

[1] Therapy of acute hepatitis C [J].

Alberti, A ;

Boccato, S ;

Vario, A ;

Benvegnú, L .

HEPATOLOGY, 2002, 36 (05) :S195-S200

[2]

BARRERA JM, 1995, HEPATOLOGY, V21, P639, DOI 10.1002/hep.1840210306

[3]

CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2

[4] Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C [J].

Gerlach, JT ;

Diepolder, HM ;

Jung, MC ;

Gruener, NH ;

Schraut, WW ;

Zachoval, R ;

Hoffmann, R ;

Schirren, CA ;

Santantonio, T ;

Pape, GR .

GASTROENTEROLOGY, 1999, 117 (04) :933-941

[5] Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance [J].

Gerlach, JT ;

Diepolder, HM ;

Zachoval, R ;

Gruener, NH ;

Jung, MC ;

Ulsenheimer, A ;

Schraut, WW ;

Schirren, CA ;

Waechtler, M ;

Backmund, M ;

Pape, GR .

GASTROENTEROLOGY, 2003, 125 (01) :80-88

[6] Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA [J].

Halfon, P ;

Khiri, H ;

Gerolami, V ;

Bourliere, M ;

Feryn, JM ;

Reynier, P ;

Gauthier, A ;

Cartouzou, G .

JOURNAL OF HEPATOLOGY, 1996, 25 (03) :307-311

[7] CLINICAL COURSE OF ACUTE HEPATITIS-C AND CHANGES IN HCV MARKERS [J].

HINO, K ;

SAINOKAMI, S ;

SHIMODA, K ;

NIWA, H ;

IINO, S .

DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (01) :19-27

[8] Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies [J].

Larghi, A ;

Zuin, M ;

Crosignani, A ;

Ribero, ML ;

Pipia, C ;

Battezzati, PM ;

Binelli, G ;

Donato, F ;

Zanetti, AR ;

Podda, M ;

Tagger, A .

HEPATOLOGY, 2002, 36 (04) :993-1000

[9] Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001 [J].

Law, MG ;

Dore, GJ ;

Bath, N ;

Thompson, S ;

Crofts, N ;

Dolan, K ;

Giles, W ;

Gow, P ;

Kaldor, J ;

Loveday, S ;

Powell, E ;

Spencer, J ;

Wodak, A .

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2003, 32 (05) :717-724

[10]

MICALLEF J, 2003, 11 INT S VIR HEP LIV, P220

← 1 2 →